RA Capital has outperformed all other healthcare hedge funds over the past decade, based on 13F holdings. In fact, RA's 30.88% annualized return of it's equal-weighted top 20 long portfolio led all other hedge funds over that period. So, when RA manager Peter Kolchinsky discloses portfolio changes,...
Protagonist Therapeutics insiders bought on Tuesday as their company's stock plummeted after preliminary data appeared to cast doubt on Protagonist's (PGTX) key drug. On Monday, the company presented an initial look at preliminary results from the TRANSCEND Ph2 open-label study of PTG-300 (hepcidin...
In the investing world, those with superior information usually make the most money. And possibly no group has better information on public companies – and profitably acts on it – than corporate insiders at small-cap biotech and medical technology companies.
On Friday afternoon, CASI Pharma CEO He Wei-Wu filed a Form 4 disclosing the purchase of nearly $7.9M of CASI stock. The insider bought the shares in a public offering of 20M CASI shares at $1.90. President Larry Zhang also bought 20,153 shares in the secondary offering,...
Billionaire Mori Arkin filed a 13D on Aclaris Therapeutics (ACRS), a development stage microcap biotech company with a promising treatment for common warts. Arkin bought the shares through his personal partnership, "The 1999 Company." In the activist filing he disclosed the following trades: Purchase/SaleSharesPriceDate Running ...
Myriad Genetics co-founder Walter Gilbert PhD bought $150K of MYGN on Dec. 13 @ $25.60. Gilbert, who won the Nobel Prize for Chemistry in 1980, has a history of Form 4 filings at Myriad dating back to 2006. However, this is the insider's first open market purchase...
Twenty-two minutes after regular market hours closed on July 2, an Orbimed Advisors Form 4 relating to Corvus Pharmaceuticals Inc (CRVS) was posted on the SEC's website. The hedge fund, a 10%+ holder and insider in CRVS, disclosed that between June 27 and July 1 it...
Engine Capital filed a 13D on Cymabay (CBAY) two weeks after the development stage biotech company halted a trial of its leading drug candidate causing it's shares to fall as much as 75%. In a 13D filing Thursday evening, New York-based Engine Capital, L.P....
Replicating Baker Brothers holdings, using 13F filings submitted quarterly by the life sciences hedge fund, has been an awesome strategy over the years. But by focusing on the smaller stocks owned by the fund, returns were even better. Baker Bros Advisors LP, with $17.33...